OTC · BRRGF
BerGenBio ASA
$97.09$0.00 (0.0%)
BerGenBio ASA’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
Loading market information…
OTC · IPCIF · USD
Stock price, earnings
Quote as of Nov 25, 2024, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Intellipharmaceutics International Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Intellipharmaceutics International Inc. operates as a pharmaceutical firm primarily engaged in the research, development, and manufacturing of both novel and generic oral solid dosage medications that feature controlled and targeted release mechanisms. The company's U.S. operations are central to its work. Leveraging its unique and patented Hypermatrix technology, Intellipharmaceutics is dedicated to creating advanced drug delivery systems and cultivating a robust pipeline of product candidates across various therapeutic domains. These include critical areas such as neurological disorders, cardiovascular health, gastrointestinal conditions, diabetes, and pain management. The company's current commercial portfolio includes a variety of extended-release and delayed-release products. These offerings address conditions like hyperactivity disorder (Focalin XR), epilepsy (Keppra XR, Lamictal XR), depression (Effexor XR, Pristiq, Seroquel XR), gastroesophageal reflux disease (Protonix), type 2 diabetes (Glucophage XR), schizophrenia and bipolar disorder (Seroquel XR), heart failure and hypertension (Coreg CR), and chronic angina (Ranexa). Additionally, Intellipharmaceutics is actively progressing several developmental compounds, such as an oxycodone hydrochloride controlled-release capsule (OxyContin) for pain management and a pregabalin extended-release capsule (Regabatin XR) designed for neuropathic pain. The company has established a licensing and commercialization partnership with Par Pharmaceutical Inc. Established in 1998, Intellipharmaceutics International Inc. is based in Toronto, Canada.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 10:32 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$97.09$0.00 (0.0%)
BerGenBio ASA’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.02+$0.00 (+12.43%)
Rhinomed Limited’s quoted price sits in the lower half of its reported 52-week range, 72.78% below the high.
$0.06+$0.01 (+32.24%)
Tryp Therapeutics Inc.’s quoted price sits in the upper half of its reported 52-week range, 38.85% below the high.
$0.00+$0.00 (+14.94%)
China Infrastructure Construction Corp.: Healthcare · Drug Manufacturers - Specialty & Generic.
$0.12+$0.00 (+2.52%)
Acreage Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 82.06% below the high.
$1.50$0.00 (0.0%)
Pixium Vision S.A.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.02+$0.00 (+6.19%)
Indiva Limited’s quoted price sits in the upper half of its reported 52-week range, 4.29% below the high.
$0.11+$0.01 (+10.0%)
Pascal Biosciences Inc.’s quoted price sits in the upper half of its reported 52-week range, 26.67% below the high.
